Dirvest

4.2 1 vote

Zimmer Biomet

About

Global medical device company specializing in orthopedic joint replacement, spine surgery, and dental implants. Aging population drives demand for joint replacements.

Aging Population Stocks

Zimmer Biomet specializes in orthopedic joint replacement, spine surgery, and dental implants, directly benefiting from aging population demographics driving increased surgical procedure volumes.

Key Financials ZBH

Price $96.45

Change (1D) +1.33%

Change (30D) +7.26%

Change (60D) +8.81%

Change (90D) -2.41%

Change (180D) +4.51%

Change (1Y) -2.57%

Change (5Y) -37.58%

P/E Ratio 8.96

EPS (TTM) $10.77

52-Week Range $84.59 — $114.44

50-Day MA $90.36

Volume 1.96M

Data updated Feb 15 · Source: Twelve Data

4.2 1 vote

AI Reviews

🤖

Claude Opus 4.6 Anthropic

4.2 /5

Zimmer Biomet is a global leader in musculoskeletal healthcare, specializing in joint replacement implants (knees, hips, shoulders) " a market directly tied to aging demographics. The company is well-positioned as global populations age and demand for orthopedic procedures grows steadily.

The bull case is compelling: ZBH trades at a remarkably low P/E of 8.96 with strong EPS of $10.77, suggesting significant undervaluation relative to its defensive healthcare positioning. The stock sits well below its 52-week high of $114.44, offering potential upside. Recent momentum is positive, with a 7.26% gain over 30 days and price above the 50-day moving average.

However, the bear case is notable. The stock has lost 37.58% over five years, reflecting persistent concerns around execution challenges, competitive pressure from Stryker and Smith+Nephew, and integration issues from the 2015 Biomet merger. Debt levels remain elevated, and surgical volume recovery post-COVID has been uneven.

For aging population investors, Zimmer Biomet offers strong demographic tailwinds and an attractive valuation, but operational improvement must materialize to unlock value. The current discount may represent opportunity for patient investors.

Category Ratings

Aging Population Stocks

4.2

Feb 15, 2026

AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more

System Prompt Used:

You are Claude Opus 4.6, an AI stock analyst for Dirvest.com - an investment directory that features curated stock listings with AI-generated reviews. Your task is to write a thoughtful, balanced investment review of the publicly traded company provided.

Guidelines:
- Write an investment-focused review based on what you know about this company and its stock
- Assess the investment thesis: financial health, growth prospects, competitive position, and risks
- If financial data is provided, reference key metrics (valuation, earnings, dividends) in your analysis
- Be balanced: mention both bull and bear cases
- Provide a rating for EACH category the item belongs to (scale 1-5, can include .1 increments like 3.1, 4.8)
- Consider the item's performance/fit within each specific category when giving ratings
- Keep the review between 80-200 words
- Write in a professional, analytical tone suitable for investors


User Prompt: Please review the following:

Name: Zimmer Biomet
Website: https://www.zimmerbiomet.com
Ticker: ZBH
Categories: Aging Population Stocks

Market Data:
- Current Price: $96.45 (1.33%)
- Change (30D): 7.26%
- Change (60D): 8.81%
- Change (90D): -2.41%
- Change (180D): 4.51%
- Change (1Y): -2.57%
- Change (5Y): -37.58%
- 52-Week High: $114.44
- 52-Week Low: $84.59
- 50-Day MA: $90.36
- Volume: 1.96M
- P/E Ratio: 8.96
- EPS (TTM): $10.77

Added: Feb 15, 2026

zimmerbiomet.com

Dirvest

Zimmer Biomet

About

Aging Population Stocks

Key Financials ZBH

AI Reviews

Category Ratings

Categories

Market insights, delivered